Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma
(2021) In European Journal of Haematology 107(2). p.275-282- Abstract
Objectives: The aim of this study was to determine risk factors for development of acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) in patients with multiple myeloma (MM). Methods: We identified all patients diagnosed with MM in Sweden from January 1st, 1958 to December 31, 2011. A total of 26 627 patients were diagnosed with MM with during the study period. Of these, 124 patients (0.5%) developed subsequent AML/MDS. For each patient with MM and a subsequent AML/MDS diagnosis, we randomly selected a matched (age, sex, and date of MM diagnosis) MM patient without a subsequent second malignancy diagnosis. Results: The cumulative melphalan exposure was significantly higher (OR = 2.8, 95% CI 1.7-5.2; P <.001) among cases... (More)
Objectives: The aim of this study was to determine risk factors for development of acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) in patients with multiple myeloma (MM). Methods: We identified all patients diagnosed with MM in Sweden from January 1st, 1958 to December 31, 2011. A total of 26 627 patients were diagnosed with MM with during the study period. Of these, 124 patients (0.5%) developed subsequent AML/MDS. For each patient with MM and a subsequent AML/MDS diagnosis, we randomly selected a matched (age, sex, and date of MM diagnosis) MM patient without a subsequent second malignancy diagnosis. Results: The cumulative melphalan exposure was significantly higher (OR = 2.8, 95% CI 1.7-5.2; P <.001) among cases (median 988 mg; IQR 644-1640) compared with controls (median 578 mg; IQR 360-967). Median time to AML/MDS development was 3.8 years (IQR 2.8-5.8). Risk of AML/MDS was not statistically altered by M protein isotype, anemia, renal failure, hypercalcemia, lytic bone lesions, or radiation therapy. Conclusion: In this nationwide population-based study, we show that increased cumulative doses of alkylating therapy with melphalan increases the subsequent risk of developing AML/MDS in patients with MM. Given improved survival in MM patients over the last decade future studies will be important to better define long-term risks.
(Less)
- author
- Jonsdottir, Gudbjorg ; Björkholm, Magnus ; Turesson, Ingemar LU ; Hultcrantz, Malin ; Diamond, Benjamin ; Porwit, Anna LU ; Landgren, Ola and Kristinsson, Sigurdur Y.
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- acute myeloid leukemia/myelodysplastic syndromes, alkylating therapy, melphalan, multiple myeloma, second malignancies
- in
- European Journal of Haematology
- volume
- 107
- issue
- 2
- pages
- 275 - 282
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85106755597
- pmid:33966293
- ISSN
- 0902-4441
- DOI
- 10.1111/ejh.13650
- language
- English
- LU publication?
- yes
- id
- 3416cba3-38ba-4c5a-b7c6-71b7f5206977
- date added to LUP
- 2021-06-24 10:17:22
- date last changed
- 2024-12-15 08:41:23
@article{3416cba3-38ba-4c5a-b7c6-71b7f5206977,
abstract = {{<p>Objectives: The aim of this study was to determine risk factors for development of acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) in patients with multiple myeloma (MM). Methods: We identified all patients diagnosed with MM in Sweden from January 1st, 1958 to December 31, 2011. A total of 26 627 patients were diagnosed with MM with during the study period. Of these, 124 patients (0.5%) developed subsequent AML/MDS. For each patient with MM and a subsequent AML/MDS diagnosis, we randomly selected a matched (age, sex, and date of MM diagnosis) MM patient without a subsequent second malignancy diagnosis. Results: The cumulative melphalan exposure was significantly higher (OR = 2.8, 95% CI 1.7-5.2; P <.001) among cases (median 988 mg; IQR 644-1640) compared with controls (median 578 mg; IQR 360-967). Median time to AML/MDS development was 3.8 years (IQR 2.8-5.8). Risk of AML/MDS was not statistically altered by M protein isotype, anemia, renal failure, hypercalcemia, lytic bone lesions, or radiation therapy. Conclusion: In this nationwide population-based study, we show that increased cumulative doses of alkylating therapy with melphalan increases the subsequent risk of developing AML/MDS in patients with MM. Given improved survival in MM patients over the last decade future studies will be important to better define long-term risks.</p>}},
author = {{Jonsdottir, Gudbjorg and Björkholm, Magnus and Turesson, Ingemar and Hultcrantz, Malin and Diamond, Benjamin and Porwit, Anna and Landgren, Ola and Kristinsson, Sigurdur Y.}},
issn = {{0902-4441}},
keywords = {{acute myeloid leukemia/myelodysplastic syndromes; alkylating therapy; melphalan; multiple myeloma; second malignancies}},
language = {{eng}},
number = {{2}},
pages = {{275--282}},
publisher = {{Wiley-Blackwell}},
series = {{European Journal of Haematology}},
title = {{Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma}},
url = {{http://dx.doi.org/10.1111/ejh.13650}},
doi = {{10.1111/ejh.13650}},
volume = {{107}},
year = {{2021}},
}